Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: FiloF who wrote (14143)	11/16/2004 9:14:01 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

increased risk of pneumonia with Prilosec This was an observational study, not a controlled study. They did not appear to control for the fact that people on Prilosec were more likely to have severe reflux than people on H2 blockers. Reflux is a known risk factor for pneumonia - people, particularly bed-ridden elederly, aspirate stomach contents, causing pneumonia. In any even the risk was very small - certainly small compared to the known risk from taking NSAIDs without Prilosec. When you are talking chronic use, the calculus may be different - there to my mind the choice becomes Celebrex or an NSAID plus Prilosec. Celebrex doesn't work quite as well as most NSAIDs (e.g., Naprosyn) and Naprosyn still appears to have a slight edge on cardioprotectiveness. Long-term nephrotoxicity (kidney damage) is a question mark with both, with the Celebrex risk still relatively unquantified and the Naprosyn risk fairly low but most definitely present. Peter